Received 693 new patient start forms for FILSPARI ® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA requesting modification of liver monitoring for FILSPARI in IgAN accepted for review by FDA; PDUFA

SAN DIEGO , Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. , (NASDAQ: TVTX) today announced that Eric Dube , Ph.D., president and chief executive officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 , at 8:15 a.m. PT .